199 related articles for article (PubMed ID: 7337678)
1. An extremely attenuated, live measles virus vaccine (CAM-EX). Persistence of low titer-antibody in institutionalized children with psychomotor retardation after vaccination.
Ueda K; Hashiguchi K; Nakashima F; Ueda S; Takahashi M
Biken J; 1981 Sep; 24(3):119-22. PubMed ID: 7337678
[TBL] [Abstract][Full Text] [Related]
2. A long-term follow-up study on the efficacy of further attenuated live measles vaccine, Biken CAM vaccine.
Isomura S; Morishima T; Nishikawa K; Hanada N; Rahman M; Terashima M; Kido S; Ueda S; Takahashi M
Biken J; 1986 Mar; 29(1):19-26. PubMed ID: 3778422
[TBL] [Abstract][Full Text] [Related]
3. [Measurement of the in vitro immune response of live attenuated measles virus vaccine and antibody levels in 0 to 10-year-old children].
Unalan H; Ustaçelebi S
Mikrobiyol Bul; 1985 Oct; 19(4):218-28. PubMed ID: 3831724
[TBL] [Abstract][Full Text] [Related]
4. Persistence of immunity against measles in persons immunized with Edmonston-Zagreb vaccine.
abu Eldan J; Borćić B; Smerdel S
Acta Med Croatica; 1991; 45(4-5):297-304. PubMed ID: 1726513
[TBL] [Abstract][Full Text] [Related]
5. [Studies on the persistence of immunity 14-15 years after vaccination with a live measles vaccine].
Zhonghua Yi Xue Za Zhi; 1989 Jul; 69(7):389-91. PubMed ID: 2598095
[No Abstract] [Full Text] [Related]
6. Persistence of vaccine-induced antibody to measles 26-33 years after vaccination.
Dine MS; Hutchins SS; Thomas A; Williams I; Bellini WJ; Redd SC
J Infect Dis; 2004 May; 189 Suppl 1():S123-30. PubMed ID: 15106101
[TBL] [Abstract][Full Text] [Related]
7. Measles immunity after revaccination: results in children vaccinated before 10 months of age.
Linnemann CC; Dine MS; Roselle GA; Askey PA
Pediatrics; 1982 Mar; 69(3):332-5. PubMed ID: 7063289
[TBL] [Abstract][Full Text] [Related]
8. A 5-year follow-up of antibody response in children vaccinated with single dose of live attenuated SA14-14-2 Japanese encephalitis vaccine: immunogenicity and anamnestic responses.
Sohn YM; Tandan JB; Yoksan S; Ji M; Ohrr H
Vaccine; 2008 Mar; 26(13):1638-43. PubMed ID: 18294743
[TBL] [Abstract][Full Text] [Related]
9. Haemagglutination inhibition antibody levels one year after natural measles infection and vaccination.
Eghafona NO; Ahmad AA; Ezeokoli CD; Emejuaiwe SO
Microbios; 1991; 67(274):33-6. PubMed ID: 1758308
[TBL] [Abstract][Full Text] [Related]
10. Antibody response after measles immunization.
Ariyasriwatana C; Kalayanarooj S; Pattamadilok S
J Med Assoc Thai; 2003 Aug; 86 Suppl 3():S701-6. PubMed ID: 14700170
[TBL] [Abstract][Full Text] [Related]
11. Persistence of measles antibodies after 2 doses of measles vaccine in a postelimination environment.
LeBaron CW; Beeler J; Sullivan BJ; Forghani B; Bi D; Beck C; Audet S; Gargiullo P
Arch Pediatr Adolesc Med; 2007 Mar; 161(3):294-301. PubMed ID: 17339511
[TBL] [Abstract][Full Text] [Related]
12. A five-year immunological follow-up study of the institutionalized handicapped children vaccinated with live varicella vaccine or infected with natural varicella.
Ueda K; Tokugawa K; Nakashima F; Takahashi M
Biken J; 1984 Sep; 27(2-3):119-22. PubMed ID: 6100048
[TBL] [Abstract][Full Text] [Related]
13. Booster vaccination with further live attenuated measles vaccine.
Bass JW; Halstead SB; Fischer GW; Podgore JK; Pearl WR; Schydlower M; Wiebe RA; Ching FM
JAMA; 1976 Jan; 235(1):31-4. PubMed ID: 945997
[TBL] [Abstract][Full Text] [Related]
14. [Epidemiological investigations on measles in unvaccinated and vaccinated children (author's transl)].
Wiedermann G; Ambrosch F
Wien Klin Wochenschr; 1976 Sep; 88(17):545-54. PubMed ID: 997537
[TBL] [Abstract][Full Text] [Related]
15. Measles susceptibility in two Pacific atoll populations. Epidemiological factors and response to live attenuated measles virus.
Willis MF; Warburton MF
Med J Aust; 1974 May; 1(20):789-93. PubMed ID: 4853112
[No Abstract] [Full Text] [Related]
16. EPI vaccines-induced antibody prevalence in 8-9 year-olds in The Gambia.
Viviani S; Mendy M; Jack AD; Hall AJ; Montesano R; Whittle HC
Trop Med Int Health; 2004 Oct; 9(10):1044-9. PubMed ID: 15482396
[TBL] [Abstract][Full Text] [Related]
17. Development of extremely attenuated live measles virus vaccine (CAM-EX).
Ueda S; Takahashi M; Kurimura T; Minekawa Y; Suzuki N
Biken J; 1972 Sep; 15(3):173-7. PubMed ID: 4643692
[No Abstract] [Full Text] [Related]
18. The status of measles after five years of mass vaccination in the USSR.
Burgasov PN; Andzaparidze OG; Popov VF
Bull World Health Organ; 1973; 49(6):571-6. PubMed ID: 4548384
[TBL] [Abstract][Full Text] [Related]
19. Cellular and humoral immune responses to measles in immune adults re-immunized with measles vaccine.
Wong-Chew RM; Beeler JA; Audet S; Santos JI
J Med Virol; 2003 Jun; 70(2):276-80. PubMed ID: 12696117
[TBL] [Abstract][Full Text] [Related]
20. [Experience with preventive measles, mumps and rubella vaccination in unified Germany].
Gerike E; Tischer A
Gesundheitswesen; 1993 Jan; 55(1):38-9. PubMed ID: 8435543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
